Literature DB >> 29397402

Interim FDG PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure?

Vít Procházka1, Lenka Henzlová2, Jaroslav Ptáček2, Tomáš Papajík3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29397402     DOI： 10.1007/s00259-018-3946-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.

Authors:  Julien Lazarovici; Marie Terroir; Julia Arfi-Rouche; Jean-Marie Michot; Sacha Mussot; Valentina Florea; Maria-Rosa Ghigna; Peggy Dartigues; Cynthia Petrovanu; Alina Danu; Christophe Fermé; Vincent Ribrag; David Ghez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-21       Impact factor: 9.236

2.  Quantitative FDG-PET: a new biomarker in PMBCL.

Authors:  Michel Meignan
Journal:  Blood       Date:  2015-08-20       Impact factor: 22.113

3.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Authors:  Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.

Authors:  Ryogo Minamimoto; Luis Fayad; Ranjana Advani; Julie Vose; Homer Macapinlac; Jane Meza; Jordan Hankins; Felix Mottaghy; Malik Juweid; Andrew Quon
Journal:  Radiology       Date:  2016-02-08       Impact factor: 11.105

5.  The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.

Authors:  Abraham Avigdor; Tsvi Sirotkin; Meirav Kedmi; Elena Ribakovsy; Miriam Berkowicz; Yaron Davidovitz; Abraham Kneller; Drorit Merkel; Yulia Volchek; Tima Davidson; Elinor Goshen; Sara Apter; Avichai Shimoni; Isaac Ben-Bassat; Arnon Nagler
Journal:  Ann Hematol       Date:  2014-03-05       Impact factor: 3.673

6.  Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

Authors:  Michel Meignan; Andrea Gallamini; Michel Meignan; Andrea Gallamini; Corinne Haioun
Journal:  Leuk Lymphoma       Date:  2009-08

Review 7.  FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.

Authors:  Sally F Barrington; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 8.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.

Authors:  Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-16       Impact factor: 9.236

9.  EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.

Authors:  Andres Kaalep; Terez Sera; Wim Oyen; Bernd J Krause; Arturo Chiti; Yan Liu; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-01       Impact factor: 9.236
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.